A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The 2026 Cardiovascular Statistics report provides a comprehensive review of trends in major cardiovascular risk factors—including hypertension, diabetes, obesity, dyslipidemia, and smoking—as well as the 5...
In part 5 of our “Test Your Knowledge” series, Michael Bloch, MD, asks you to review the patient vignette and choose the best course of action in terms of pharmacological therapy.
In part 1 of our “Test Your Knowledge” series, Michael Bloch, MD, asks you to pick the patient vignette that best defines resistant hypertension as defined by the ACC/AHA.
In this video, Aldis H. Petriceks, BA, discusses his team's study, which set out to determine the optimal timepoints for assessing orthostatic hypotension in older adults, as well as the association between...
In this video, Anum Minhas, MD, MHS, discusses the potential cardiovascular risks of estrogens and progestins, the contraceptive recommendation for patients seeking to avoid pregnancy and have a high risk...
In this video, Anum Minhas, MD, MHS, discusses recommendations for contraceptives in women with heart disease, obesity, high blood pressure, or diabetes in a cardiology setting, including dependable...
In this podcast, Dr Harrison and Paul Shiu, DO, discuss hypertension urgency and emergency, what happens if hypertension is not properly managed, managing hypertension in the elderly, and in women who are...
In this article, Michael J. Bloch, MD, writes about orthostatic hypotension (OH), which is a frequent problem in patients with hypertension, including the approach to diagnosis and management of patients...